cspc pharmaceutical group ltd. - CSPCY

CSPCY

Close Chg Chg %
3.49 -0.10 -2.98%

Open Market

3.39

-0.10 (2.98%)

Volume: 133.00

Last Updated:

Jun 25, 2026, 11:17 AM EDT

Company Overview: cspc pharmaceutical group ltd. - CSPCY

CSPCY Key Data

Open

$3.39

Day Range

3.39 - 3.39

52 Week Range

3.36 - 5.83

Market Cap

$9.97B

Shares Outstanding

2.88B

Public Float

2.88B

Beta

0.35

Rev. Per Employee

N/A

P/E Ratio

18.32

EPS

$0.09

Yield

283.39%

Dividend

$0.06

EX-DIVIDEND DATE

Jun 25, 2026

SHORT INTEREST

N/A

AVERAGE VOLUME

2.69K

 

CSPCY Performance

1 Week
 
1.28%
 
1 Month
 
-11.09%
 
3 Months
 
-24.98%
 
1 Year
 
-11.32%
 
5 Years
 
-40.68%
 

CSPCY Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings
Full Ratings ➔

About cspc pharmaceutical group ltd. - CSPCY

CSPC Pharmaceutical Group Ltd. is an investment holding company, which is engaged in the manufacturing and selling of pharmaceutical products. It operates through the following business segments: Finished Drugs, Antibiotics, Vitamin C, Caffeine and Others. The company was founded on August 21, 1997 and is headquartered in Shijiazhuang, China.

CSPCY At a Glance

CSPC Pharmaceutical Group Ltd.
No.896 Zhongshandong Street
Shijiazhuang, Hebei 050035
Phone 86-311-8703-7015 Revenue 3.62B
Industry Biotechnology Net Income 540.05M
Sector Health Technology Employees 19,700
Fiscal Year-end 12 / 2026
View SEC Filings

CSPCY Valuation

P/E Current 18.451
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 22.909
Price to Sales Ratio 3.42
Price to Book Ratio 2.614
Price to Cash Flow Ratio 14.69
Enterprise Value to EBITDA 15.21
Enterprise Value to Sales 3.149
Total Debt to Enterprise Value 0.008

CSPCY Efficiency

Revenue/Employee 183,641.892
Income Per Employee 27,413.605
Receivables Turnover 2.648
Total Asset Turnover 0.567

CSPCY Liquidity

Current Ratio 2.186
Quick Ratio 1.883
Cash Ratio 0.871

CSPCY Profitability

Gross Margin 65.595
Operating Margin 15.282
Pretax Margin 18.69
Net Margin 14.928
Return on Assets 8.462
Return on Equity 11.781
Return on Total Capital 11.159
Return on Invested Capital 11.738

CSPCY Capital Structure

Total Debt to Total Equity 1.932
Total Debt to Total Capital 1.896
Total Debt to Total Assets 1.373
Long-Term Debt to Equity 0.545
Long-Term Debt to Total Capital 0.534
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Cspc Pharmaceutical Group Ltd. - CSPCY

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
4.59B 4.44B 4.03B 3.62B
Sales Growth
+6.33% -3.38% -9.19% -10.25%
Cost of Goods Sold (COGS) incl D&A
1.29B 1.31B 1.21B 1.24B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
155.31M 157.26M 185.66M 196.07M
Depreciation
141.89M 145.56M 164.94M 174.54M
Amortization of Intangibles
13.42M 11.69M 20.71M 21.53M
COGS Growth
+23.50% +1.53% -7.53% +2.84%
Gross Income
3.31B 3.13B 2.82B 2.37B
Gross Income Growth
+0.86% -5.30% -9.89% -15.86%
Gross Profit Margin
+71.94% +70.51% +69.97% +65.59%
2022 2023 2024 2025 5-year trend
SG&A Expense
2.30B 2.14B 2.08B 1.82B
Research & Development
592.02M 681.77M 721.24M 808.07M
Other SG&A
1.71B 1.46B 1.36B 1.01B
SGA Growth
-0.50% -6.76% -3.05% -12.35%
Other Operating Expense
- - - -
-
Unusual Expense
(21.72M) 23.40M 14.52M (46.67M)
EBIT after Unusual Expense
1.03B 964.73M 729.31M 599.55M
Non Operating Income/Expense
102.29M 89.54M 64.36M 81.99M
Non-Operating Interest Income
36.02M 36.68M 32.31M 27.25M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
3.70M 3.66M 6.07M 5.37M
Interest Expense Growth
+211.06% -1.12% +66.03% -11.52%
Gross Interest Expense
3.70M 3.66M 6.07M 5.37M
Interest Capitalized
- - - -
-
Pretax Income
1.13B 1.05B 787.60M 676.16M
Pretax Income Growth
+6.63% -6.89% -25.03% -14.15%
Pretax Margin
+24.56% +23.67% +19.54% +18.69%
Income Tax
200.52M 185.84M 172.28M 129.61M
Income Tax - Current - Domestic
196.40M 199.82M 200.77M 123.45M
Income Tax - Current - Foreign
1.93M 1.59M 846.90K 3.98M
Income Tax - Deferred - Domestic
2.19M (15.57M) (29.33M) 2.18M
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
925.50M 857.12M 602.88M 539.25M
Minority Interest Expense
20.89M 28.14M 1.50M (795.44K)
Net Income
904.61M 828.98M 601.38M 540.05M
Net Income Growth
+4.08% -8.36% -27.45% -10.20%
Net Margin Growth
+19.69% +18.68% +14.92% +14.93%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
904.61M 828.98M 601.38M 540.05M
Preferred Dividends
- - - -
-
Net Income Available to Common
904.61M 828.98M 601.38M 540.05M
EPS (Basic)
0.3036 0.2793 0.2049 0.1891
EPS (Basic) Growth
+4.40% -8.00% -26.64% -7.71%
Basic Shares Outstanding
2.98B 2.97B 2.93B 2.86B
EPS (Diluted)
0.3036 0.2793 0.2049 0.1891
EPS (Diluted) Growth
+4.40% -8.00% -26.64% -7.71%
Diluted Shares Outstanding
2.98B 2.97B 2.93B 2.86B
EBITDA
1.16B 1.15B 929.48M 748.94M
EBITDA Growth
+5.54% -1.54% -18.85% -19.42%
EBITDA Margin
+25.32% +25.80% +23.06% +20.70%

Cspc Pharmaceutical Group Ltd. in the News